Related Experiment Video
Updated: Feb 1, 2026
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Effect of Clopidogrel vs Ticagrelor on Platelet Aggregation and Inflammation Markers After Percutaneous Coronary
Zaixin Jiang1, Ruoxi Zhang2, Meng Sun2
1Department of Cardiology, The 1st Hospital of Qiqihar, Qiqihar, China.
Insights
Ticagrelor offers superior platelet inhibition compared to clopidogrel in ST-elevation myocardial infarction patients with high inflammation. This suggests ticagrelor may provide a more stable antiplatelet effect and reduce inflammation post-percutaneous coronary intervention.
Area of Science:
- Cardiology
- Pharmacology
- Inflammation Research
Background:
- Acute coronary syndrome (ACS) triggers an inflammatory response impacting platelet aggregation.
- Understanding the interplay between inflammation severity and antiplatelet therapy efficacy is crucial for ST-elevation myocardial infarction (STEMI) patients undergoing percutaneous coronary intervention (PCI).
Purpose of the Study:
- To investigate the relationship between inflammation severity and the effectiveness of antiplatelet therapy (clopidogrel vs. ticagrelor) in STEMI patients post-PCI.
- To assess whether ticagrelor offers superior platelet inhibition compared to clopidogrel in the context of varying inflammation levels.
Main Methods:
- Retrospective study of 203 STEMI patients undergoing primary PCI.
- Stratification based on pre-PCI inflammation levels (low, intermediate, high) using C-reactive protein.
- Comparison of residual adenosine diphosphate-induced platelet reactivity between clopidogrel and ticagrelor users.
Main Results:
- Ticagrelor demonstrated significantly higher platelet inhibition than clopidogrel at intermediate and high inflammation levels.
- Clopidogrel users showed varying platelet aggregation across inflammation levels.
- Ticagrelor users exhibited reduced inflammatory markers (interleukin-1β) and increased anti-inflammatory markers (interleukin-35, transforming growth factor-β) at 1-year follow-up.
Conclusions:
- Ticagrelor provides more potent and stable platelet inhibition than clopidogrel, particularly in STEMI patients with higher systemic inflammation.
- Ticagrelor's associated reduction in inflammatory markers suggests potential anti-inflammatory benefits, supporting its use in STEMI patients post-PCI.
Background:
Patients with acute coronary syndrome show an inflammatory response that is known to affect platelet aggregation. We aimed to clarify the relationship between the inflammation severity and the effect of antiplatelet therapy after percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI).
Methods:
This retrospective, single-center study included 203 patients with STEMI who underwent primary PCI and were stratified on the basis of the antiplatelet therapy on admission (clopidogrel vs ticagrelor). Inflammation levels were defined as low, intermediate, and high, based on the tertiles of the distribution of high-specificity C-reactive protein levels pre-PCI. Platelet aggregation function during hospitalization and follow-up was quantified as residual adenosine diphosphate-induced platelet reactivity on light transmittance aggregometry. Inflammation markers were measured on admission and at 1 year post-PCI.
Results:
At intermediate and high levels of inflammation, residual adenosine diphosphate-induced platelet aggregation was significantly higher among clopidogrel users than among ticagrelor users. In the clopidogrel group, statistically significant differences in platelet aggregation function were observed among the 3 levels of inflammation. At 1 year post-PCI, ticagrelor users had significantly lower levels of interleukin-1β and higher levels of interleukin-35 and transforming growth factor-β.
Conclusion:
At different inflammation levels, ticagrelor provides more potent platelet inhibition than clopidogrel, suggesting that ticagrelor might exert a more stable antiplatelet effect at higher levels of systemic inflammation. Furthermore, ticagrelor is associated with reduced indices of inflammation on follow-up after PCI, suggesting that anti-inflammatory effects might play a role in the clinical benefit observed with antiplatelet therapy, which would provide an additional rationale for using ticagrelor in patients with STEMI undergoing primary PCI.
More Related Videos
Related Concept Videos
01:38Inflammation
03:12Freezing Point Depression and Boiling Point Elevation
The boiling point of a liquid is the temperature at which its vapor pressure is equal to ambient atmospheric pressure. Since the vapor pressure of a solution is lowered due to the presence of nonvolatile solutes, it stands to reason that the solution’s boiling point will subsequently be increased. Vapor pressure increases with temperature, and so a solution will require a higher temperature than will pure solvent to achieve any given vapor pressure, including one...
01:03Nursing Interventions I: Taxonomy of Nursing Interventions
A nursing intervention is a treatment or action based on scientific concepts and knowledge from the nursing, behavioral, and physical sciences. Identifying and prioritizing nursing interventions based on the desired outcome...
01:29Nursing Interventions II: Selecting and Classifying the Nursing Interventions
01:20Elevation of Intermediate Points on Vertical Curves
01:21Coronary Circulation
Coronary circulation begins at the base of the aorta, where two main arteries arise—the left and right coronary arteries. These arteries encircle the heart in the coronary sulcus and supply the...